Salvage Cytoreductive Surgery for Recurrent XXXX .

@entity1 @entity1204 @entity41 @entity1104 @entity204 @entity1349
OBJECTIVE: The aim of this study was to determine the effect of @entity1104 ( @entity1104 ) on @entity1349 ( @entity1349 ) among @entity1 with recurrent @entity1204 and if there is any predictor for @entity41 status. METHODS: Between January 1993 and May 2013, data of 34 @entity1 who had @entity1104 for recurrent @entity1204 were retrospectively analyzed. Overall survival was determined from @entity1104 to last follow-up. RESULTS: The surgical procedure was local excision without laparotomy in 12 @entity1 , and optimal cytoreduction (no visible disease) was achieved in 24 of 34 @entity1 . There were no perioperative @entity204 . None of the factors was associated with achievement of optimal cytoreduction. Five-year @entity1349 rates were 37% and 27% for the entire cohort and for the laparotomy group, respectively. For the entire cohort, disease-free interval (from initial surgery to recurrence), adjuvant therapy after initial surgery, CA-125 level at recurrence, multiplicity of recurrence, surgical procedure, and optimal cytoreduction and for the laparotomy group adjuvant treatment and optimal cytoreduction were associated with @entity1349 . In the laparotomy group, @entity1349 rates were 53 and 9 months in the @entity1 who did and did not have optimal @entity1104 , respectively. CONCLUSIONS: Significant survival benefit can be achieved with optimal resection. Prospective studies should be designed to define optimal cytoreduction and to determine the predictors of optimal cytoreduction achievement.
